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Highlights 
 Cholecalciferol supplementation in patients with CKD and vitamin D deficiency 
improved endothelial function (FMD) and vascular stiffness (PWV) 
 NMD also improved which is a novel finding and needs to be explored further 
 PTH decreased with cholecalciferol supplementation 
 FGF-23 also decreased with cholecalciferol supplementation unlike previously 
reported increase with use of activated vitamin D 
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Abstract 
Vitamin D deficiency is common and associated with mortality in chronic kidney 
disease (CKD) patients. Cardiovascular disease (CVD) is the commonest cause of 
mortality in CKD patients. In a randomized, double blind, placebo controlled trial, we 
have recently reported favorable effects of vitamin D supplementation on vascular & 
endothelial function and inflammatory biomarkers in vitamin D deficient patients with 
non-diabetic stage 3-4 CKD (J Am Soc Nephrol 28: 3100–3108, 2017). Subjects in the 
placebo group who had still not received vitamin D after completion of the trial received 
two oral doses 300000 IU of oral cholecalciferol at 8 weeks interval followed by flow 
mediated dilatation (FMD), pulse wave velocity (PWV), circulating endothelial and 
inflammatory markers (E-Selectin, vWF, hsCRP and IL-6), 1,25 (OH)2D, iPTH and 
iFGF-23 assessment at 16 weeks. 31 subjects completed this phase of the study. Last 
values recorded in the preceding clinical trial were taken as baseline values. Serum 
25(OH)D and 1,25(OH)2D increased and FMD significantly improved after 
cholecalciferol supplementation [mean change in FMD%: 5.8% (95% CI: 4.0-7.5%, 
p<0.001]. Endothelium independent nitroglycerine mediated dilatation, PWV, iPTH, 
iFGF-23 and IL-6 also showed favorable changes. The data further cement the 
findings of beneficial effects of correction of vitamin D deficiency on vascular function.  
 
Abbreviations 
1,25(OH)2D 1,25-Dihydroxyvitamin D  
25(OH)D 25-Hydroxyvitamin D 
AKI  Acute kidney injury 
BAP  Bone-specific alkaline phosphatase 
CKD  Chronic kidney disease 
CVD  Cardiovascular disease 
CTX-1  Serum C-terminal cross-linked collagen type I telopeptides 
EIA  Enzyme immunoassay 
ELISA  Enzyme linked immunosorbent assay 
FMD  Endothelium dependent flow mediated dilatation 
hs-CRP High sensitivity C reactive protein 
iFGF-23 Intact fibroblast growth factor-23 
IL-6  Interleukin-6 
iPTH  Intact parathormone 
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NMD  Endothelium independent nitroglycerine mediated dilatation 
PWV  Pulse wave velocity 
RAAS  Renin angiotensin aldosterone system 
SAP  Serum total alkaline phosphatase 
vWF  Von willebrand factor 
 
 
Keywords 
Vitamin D, chronic kidney disease, cardiovascular disease, flow mediated dilatation, 
pulse wave velocity 
 
 
1. Introduction 
Vitamin D deficiency is common in patients with chronic kidney disease (CKD) [1]. 
Unlike normal individuals in which vitamin D deficiency is ascribed to reduced sun 
exposure or intake, patients with CKD have an additional risk factor as kidney is the 
major site for final conversion of various dietary forms of vitamin D to active form i.e. 
1,25-dihydroxyvitamin D [1,25(OH)2D]. Cardiovascular disease (CVD) is the most 
common cause of mortality in patients with CKD and has been associated with vitamin 
D deficiency [2, 3]. Till recently, the main therapeutic target of replenishing vitamin D 
in CKD has been maintenance of altered bone and mineral health. However, 
observational data linking vitamin D deficiency to hypertension, CVD and mortality in 
CKD [4] has prompted investigations into effect of vitamin D replenishment on 
cardiovascular health. Recently we published the results of a randomized, double 
blind, placebo controlled clinical trial in which 120 adult subjects with nondiabetic CKD 
stage G3–4 and vitamin D deficiency (serum 25(OH)D ≤20 ng/ml) were randomized 
to receive either two directly observed oral doses of cholecalciferol (300,000 IU) or 
matching placebo at baseline and 8 weeks [5]. High bolus doses ensure compliance 
and have been shown to be effective in increasing circulating 25(OH)D levels [6, 7]. 
The intervention significantly improved vascular function as shown by increased 
endothelium-dependent brachial artery flow-mediated dilation (FMD) in the 
cholecalciferol group [between-group difference in mean change (5.49%; 95% 
confidence interval, 4.34% to 6.64%; P,0.0010 [5]. The results were concordant with 
the improvement in FMD that has been reported earlier with use of paricalcitol in 
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patients with CKD stage 3-4 in Paricalcitol and Endothelial Function in Chronic Kidney 
Disease (PENNY) trial [8]. In addition, endothelium-independent nitroglycerine 
mediated dilatation (NMD) and pulse wave velocity (PWV) also improved after 
cholecalciferol supplementation. As cholecalciferol supplementation significantly 
improved vascular function in our previous clinical trial, we decided to investigate 
whether it would similarly affect vascular function in subjects who were enrolled in the 
placebo arm and had not received it. 
 
 
In this paper, we report the change in FMD, PWV, NMD and biomarkers in subjects 
who were enrolled in the placebo arm and received cholecalciferol supplementation 
after completion of clinical trial and removal of blinding.  
 
2. Material and methods 
2.1 Study setting, design, population and enrolment 
The present study is a self-controlled case series which reports follow up of subjects 
who were enrolled in the placebo arm of the randomized, double blind, placebo 
controlled clinical trial (CTRI/2013/05/003648) and who subsequently received vitamin 
D supplementation in similar manner after completion of this clinical trial [5]. After 
completion of clinical trial and removing of blinding, subjects in the placebo group who 
were clinically stable and had still not received any form of vitamin D supplementation 
after exit from the clinical trial were eligible for enrolment.  
 
2.2 Study intervention and follow up 
All enrolled subjects prospectively received two directly observed oral doses of 
cholecalciferol (300,000 I.U. each) 8 weeks apart. This was followed by 
measurements at 16 weeks as described below.  
 
2.3 Study measurements 
The last values recorded in clinical trial were extracted from trial database and taken 
as baseline values for the purpose of this study [5]. One time measurements done as 
part of this study (after cholecalciferol supplementation) were taken as follow up 
measurements. FMD and NMD were measured as described previously [5] in fasting 
state using Philips IU22 xMatrix ultrasound system (Philips, Cambridge, MA), Philips 
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IU22 L12–5 linear transducer with extended operating frequency range of 5–12 MHz. 
Recordings were analyzed in a random order by a blind independent investigator, 
using Brachial Analyzer for Research 6 (Vascular Research Tools 6; Medical Imaging 
Applications LLC, Coralville, IA), an automated continuous edge detection and wall 
tracking software. Carotid-femoral PWV were calculated using the SphygmoCor CPV 
system (AtCor Medical, Inc., Itasca, IL) on the same day as the brachial artery FMD 
assessment.  
 
Plasma and serum samples at follow up visit were stored at -80°C. Serum 1,25(OH)2D 
[Enzyme immunoassay (EIA); Immunodiagnostic Systems], serum intact 
parathormone (iPTH) (EIA; Calbiotech Inc., El Cajon, CA), serum intact fibroblast 
growth factor-23 (iFGF-23) [second-generation enzyme linked immunosorbent assay 
(ELISA); Immutopics, Inc., Athens, Ohio], serum E-selectin (Quantikine solid-phase 
sandwich ELISA; R&D Systems, Minneapolis, MN), serum high sensitivity C reactive 
protein (hs-CRP) (Quantikine solid- phase sandwich ELISA; R&D Systems), serum 
interleukin-6 (IL-6) (Quantikine solid- phase sandwich ELISA; R&D Systems), and 
plasma von Willebrand factor (vWF) (IMUBIND ELISA; Sekisui Diagnostic, Lexington, 
MA) were analyzed in all samples.  
 
2.4 Study outcomes 
The main outcome was change in brachial artery FMD. Other outcome measures were 
changes in PWV and levels of serum 1,25(OH)2D, serum iPTH, serum FGF-23, serum 
E-selectin, serum hs-CRP, serum IL-6, and plasma vWF. 
 
2.5 Statistical considerations 
All enrolled patients with non-missing outcome data were included in the analysis. 
Categorical data were expressed as frequencies and continuous data were expressed 
as mean (±standard deviation) or median (interquartile range) whichever was 
appropriate. Paired t test or Wilcoxon signed-rank test were used as appropriate for 
comparing baseline and follow up measurements. Two-tailed P values ≤0.05 were 
considered statistically significant. An analysis was conducted using SPSS software 
for Macintosh, version 21.0 (IBM SPSS, Chicago, IL).  
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Data from clinical trial (mean change in FMD%: -0.07±2.45 and 5.42±3.70 in the 
placebo and cholecalciferol groups, respectively) has shown that a sample size of 6 
subjects would have been adequate to detect any significant difference of 
cholecalciferol supplementation on FMD in crossover or self-controlled design with 
80% power and two-sided alpha of 0.05.  
 
3. Results 
3.1 Study subjects 
Between October-December 2015, 59 subjects who had completed the trial protocol 
in placebo group were called. A total of 52 subjects responded, out of whom 18 had 
received cholecalciferol after completing the study and one had developed AKI 
associated with tropical acute febrile illness and hence were excluded. Remaining 33 
eligible subjects consented and received intervention. However, only 31 subjects 
completed study measurements at follow up. The mean duration between baseline 
and follow up measurements was 42.7±10.6 (range 22-56) weeks. 
 
3.2 Baseline and follow up measurements 
The demographic characteristics of study population are shown in table 1. Two thirds 
were males and cause of CKD was unknown in 50% of subjects. Around 94% were 
hypertensive and 13% had family history of kidney disease. Table 2 shows selected 
biochemical parameters, biomarkers and vascular function measurements at baseline 
and follow up in study subjects. Serum creatinine remained similar over the study 
period. Serum calcium showed an increasing trend but the results did not reach 
statistical significance [mean change in serum calcium: 0.61 mg/dl (95% CI: -0.02 to 
1.24 mg/dl), p=0.06]. Serum 25-Hydroxyvitamin D [25(OH)D] and 1,25(OH)2D levels 
increased significantly after cholecalciferol supplementation. FMD significantly 
improved after cholecalciferol supplementation [mean change in FMD%: 5.8% (95% 
CI: 4.0-7.5%), p<0.001]. Similarly, NMD [mean change in NMD%: 5.1% (95% CI: 2.8 
to 7.5%), p<0.001] and PWV [mean change in PWV: -0.76 m/s (95% CI: -1.3 to -
0.25m/s), p=0.005] also changed favorably. Serum iPTH [mean change in iPTH: -92.3 
ng/ml (95% CI: -172.9 to -11.7 ng/ml), p=0.019], IL-6 [mean change in IL-6: -1.7 pg/ml 
(95% CI: -2.8 to -0.5 pg/ml), p=0.002] and iFGF-23 [mean change in iFGF-23: -21.5 
pg/ml (95% CI: -46.8 to 3.8 pg/ml), p=0.005] significantly decreased after 
supplementation.  
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4. Discussion 
The improvement in endothelial function and vascular stiffness after cholecalciferol 
supplementation as shown by favorable changes in FMD, NMD and PWV in this self-
controlled phase is concordant with the results reported in the preceding clinical trial 
[5]. Reproduction of similar results is a major advantage of the present study. We also 
observed a decrease in iPTH and IL-6 levels, as well as decrease in iFGF-23 levels 
which is in line with the trend towards lower iFGF-23 levels after cholecalciferol 
supplementation in the intervention group in the preceding clinical trial [5]. Serum 
calcium and phosphorus levels remained similar though serum calcium levels did 
show an increasing trend which emphasizes the need of monitoring serum calcium 
levels while on cholecalciferol therapy. 
 
Since our study was published, two other randomized controlled trials have been 
published which explored the impact of various forms of vitamin D supplementation 
on short term surrogate cardiovascular outcomes. In the randomized, placebo 
controlled trial by Levin et al. that evaluated the effect of calcifediol (5000 IU thrice 
weekly) or calcitriol (0.5 µg) thrice weekly on PWV in 119 stable subjects with CKD 
stage 3b-4 on renin angiotensin aldosterone system (RAAS) blocking drugs 
irrespective of circulating 25(OH)D levels, PWV increased in placebo group, remained 
similar in calcitriol group and decreased in calcifediol group at 6 months [9]. When 
calcifediol and calcitriol groups were combined together, PWV significantly declined in 
combined vitamin D intervention group as compared to the placebo [9]. In another 
randomized controlled trial. that investigated the effect of oral cholecalciferol (2000 IU 
daily) or calcitriol (0.5 µg daily) on FMD in subjects with CKD stage 3b-4 and vitamin 
D levels <30 ng/ml, no significant difference in changes in FMD were observed either 
within or between groups at 6 months [10]. The lack of a placebo arm in this trial 
prevents a meaningful comparison with our results [5]. Racial differences, relatively 
younger subjects, exclusion of subjects with diabetes, higher mean dose of 
cholecalciferol (approximately 5000 IU daily), selection of subjects with relatively 
severe vitamin D deficiency [25(OH)D levels ≤20 ng/ml] and shorter duration of follow 
up in our studies might be responsible for the observed differences. All these 
aforementioned studies had small sample sizes, different designs and interventions, 
but together with previously published small studies and clinical trials, these results do 
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suggest possible short term favorable modulation of vascular function by vitamin D 
supplementation [8] [11] [12] [13] [14].  
 
Vitamin D supplementation in subjects with CKD is usually advocated in the form of 
activated vitamin D compounds like calcitriol or paricalcitol as it is presumed that native 
forms of vitamin D would not get converted to 1,25(OH)2D, on account of decreased 
functioning renal parenchymal mass in CKD. However, our results suggest that even 
in patients with CKD stage G3-4 and vitamin D deficiency there is a significant increase 
in circulating 1,25(OH)2D levels after cholecalciferol supplementation [serum 25(OH)D 
levels at baseline and follow up: 15.7±9.8 versus 34.7±14.5 ng/ml, respectively, 
p<0.001; serum 1,25(OH)2D levels at baseline and follow up: 21.4±20.2 versus 
40.1±18.7 pg/ml, respectively, p<0.001]. At present, it is difficult to determine whether 
the effects after cholecalciferol supplementation in our current study and preceding 
clinical trial are independent or mediated through increase in 1,25(OH)2D.  
 
We have also shown that cholecalciferol supplementation decreased iPTH and bone 
turnover markers. In a secondary analysis of our clinical trial, we have shown that 
serum total and bone-specific alkaline phosphatase (SAP, BAP) and serum C-terminal 
cross-linked collagen type I telopeptides (CTX-1) were significantly reduced in 
cholecalciferol group [15]. This suggests that just cholecalciferol supplementation was 
able to suppress secondary hyperparathyroidism and improve bone turnover. The 
magnitude of decrease in iPTH in our study and preceding clinical trial was similar to 
what has been reported with use of activated forms of vitamin D by [8]. However, the 
decrease in iFGF-23 in our study is in contrast to what has been observed with use of 
activated vitamin D compounds. In the trial by Kendrick et al., FGF-23 significantly 
increased in both calcitriol and cholecalciferol groups at 6 months [10]. The authors 
did not relate this to vitamin D repletion and suggested that this could be reflective of 
increase in FGF-23 with time in CKD population. Paricalcitol use (2 µg/day) was 
associated with increase in FGF-23 levels at 12 weeks in randomized, placebo 
controlled PENNY trial that showed improvement in FMD in subjects with CKD stage 
3-4 and PTH >65 pg/ml [8] [16]. These observations need further exploration as 
increasing levels of FGF-23 have been associated with adverse cardiovascular 
outcomes in CKD [17]. Also, this suggests that there could be mechanistic differences 
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between vitamin D supplementation by native or activated vitamin D compounds in 
CKD.  
 
A novel and potentially interesting finding of our RCT was the increase in NMD, which 
was also noted in this phase. As vascular endothelium and smooth muscle cell 
functions are intricately linked and vitamin D receptor expression is well known in both 
types of tissue, it would be interesting to investigate whether these results are due to 
independent modulation of vascular smooth muscle cell function over and above the 
endothelium.  
 
Long term and well-designed studies are needed to investigate the effect of vitamin D 
supplementation on long term cardiovascular risk reduction, examination of the 
magnitude of effect across various patient subgroups, differences between effects of 
activated and native forms of vitamin D in CKD, effect modification due to degree of 
vitamin D deficiency and the possible mechanisms of improvement in vascular 
function beyond modulation of endothelial function. 
 
5. Conclusions 
The present study reaffirms the favorable effects of cholecalciferol supplementation 
on vascular function in subjects with CKD and vitamin D deficiency. Though 
uncontrolled observational design is a major limitation, the fact that it replicates the 
effects seen in the original clinical trial does add to the limited evidence that we have 
in this regard.  
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Tables 
Table 1: Baseline and demographic characteristics of study population (n=31) 
Parameter Value 
Gender (M/F) 21/10 
Age (years) 45.39±11.80 
Body mass index (kg/m2) 24.64±4.40 
SBP (mmHg) 128.30±12.34 
DBP (mmHg) 80.90±14.37 
Fasting blood sugar (mg/dl) 88.06±13.08 
Duration of CKD (months) 37.8±46.8 
Smoking history, N (%) 4 (12.9) 
Hypertension, N (%) 29 (93.5) 
Family history of kidney disease 4 (12.9) 
Family history of diabetes 9 (29.0) 
Family history of hypertension 12 (38.7) 
Cause of CKD  
Unknown 16 (51.6) 
Chronic interstitial nephritis 6 (19.4) 
Chronic glomerulonephritis 4 (12.9) 
Polycystic kidney disease 3 (9.6) 
Others 2 (6.5) 
Medications  
ACE inhibitor/ARB 19 (61.3) 
Beta Blockers 7 (22.6) 
Statins 9 (29.0) 
Hypouricemic agents 9 (29.0) 
Calcitriol 1 (3.2) 
Calcium based phosphate binders 1 (3.2) 
Sodium bicarbonate 20 (64.5) 
Calcium-channel blockers 20 (64.5) 
Data presented as mean ± SD or number (percentage). SBP, systolic BP; DBP, 
diastolic BP; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor 
blockers.  
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Table 2: Change in biochemical parameters, blood pressure, vascular function 
and biomarkers in study population (n=31) 
    
Parameter Baseline Follow up P value 
SBP (mmHg) 128.30±12.34 126.20±19.43 0.496 
DBP (mmHg) 80.90±14.37 80.06±11.50 0.749 
FMD (%) 8.0±2.7 13.8±4.3 <0.001 
NMD (%) 11.0±3.2 16.1±5.9 <0.001 
FMD/NMD 0.77±0.31 0.93±0.42 0.107 
PVW (m/sec) 8.0±1.3 7.3±1.3 0.005 
AI (%) 16.4±12.6 18.0±13.8 0.417 
Serum Urea (mg/dl) 62.06±27.53 61.08±27.40 0.903 
Serum creatinine 2.36±1.73 2.24±0.96 0.678 
Uric Acid (mg/dl) 7.47±2.11 7.12±1.86 0.195 
Serum total protein (mg/dl) 7.32±0.71 6.96±1.46 0.155 
Serum albumin (mg/dl) 4.42±0.68 4.09±0.87 0.079 
Calcium (mg/dl) 8.42±1.20 9.00±0.59 0.056 
Inorganic phosphate mg/dl) 3.40±1.02 3.35±0.87 0.752 
Alkaline phosphatase (mg/dl) 124.8±47.6 121.6±39.5 0.647 
Total Cholesterol (mg/dl) 160.50±43.38 159.20±43.64 0.784 
Triglyceride (mg/dl) 145.50±66.64 175±102.3 0.241 
25(OH) Vit D (ng/ml) 15.7±9.8 34.7±14.5 <0.001 
1,25(OH)2 Vit D (pg/ml) 21.4±20.2 40.1±18.7 0.001 
iPTH (ng/ml)* 186 (101, 293) 119 (87-172) 0.019 
E-selectin (ng/ml) 54.2±22.0 51.6±18.0 0.316 
IL-6 (pg/ml)* 3.3 (2.3, 5.5) 2.7 (1.9-4.5) 0.002 
hs-CRP (mg/L) 3.0±2.9 3.3±2.5 0.775 
iFGF-23 (pg/ml)* 52.3 (42.9, 78.4) 32.0 (27.4-50.6) 0.005 
vWF (mU/ml) 1076±379 1225±253 0.103 
Data presented as mean±SD or median (25th, 75th percentile). 25(OH)D, 25-
hydroxyvitamin D; 1,25(OH)2D, 1,25-dihydroxyvitamin D; AI, Augmentation index; 
FMD, endothelium dependent flow-mediated dilation; hs-CRP, high sensitivity C 
reactive protein; IL-6, Interleukin 6; iFGF-23, intact fibroblast growth factor 23; iPTH, 
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intact para- thyroid hormone; NMD, endothelium independent nitroglycerine mediated 
dilation; vWF, von Willebrand factor. *Compared using Wilcoxon signed-rank test 
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